OncoAlert Weekly Roundup🚨 August 15-21, 2025 / AMPLIFY201, IMvigor011 Update in

Описание: 🎯 Personalization in Cancer Care | OncoAlert Weekly Roundup (Breast, Bladder, GI, Lung, Prostate & More)

Description:
Welcome to this week’s OncoAlert Weekly Roundup—your 4-minute source for the most important updates in oncology. I’m Gil Morgan, and this week’s theme is clear: personalization is becoming the standard in cancer care.

🔑 Highlights from this episode:
Breast Cancer: Patient vs physician perspectives on brain imaging, ctDNA insights after CDK4/6 inhibitor progression, and global consensus on regional nodal irradiation.
Bladder Cancer: IMvigor011 trial confirms adjuvant atezolizumab benefits ctDNA-positive patients, alongside breakthrough advances like TAR-200 and EV+pembro.
GI Oncology: ELI-002 mKRAS vaccine shows promise in MRD settings; rectal cancer care shifts toward TNT, organ preservation, and biomarker-driven strategies.
Lung Cancer: SAVANNAH trial highlights savolitinib + osimertinib in MET-driven resistance; review of KEAP1/SMARCA4/PTEN in immunotherapy resistance.
Prostate & Gynecologic Oncology: MRI-led active surveillance for prostate cancer risk stratification; new low-risk criteria for co-existent endometrial/ovarian cancer.
Oncology Tech: How AI is reshaping detection, treatment planning, and survivorship.

📌 Take Home Message:
From brain imaging in breast cancer to AI across oncology, precision medicine is no longer a future goal—it’s happening now.

🔗 Explore more in our weekly newsletter: www.oncoalert360.com

✨ Stay ahead in oncology:
👍 Like this video to support the channel.
✅ Subscribe for weekly oncology updates in under 5 minutes.
🔔 Turn on notifications so you never miss a roundup.
💬 Join the conversation: Which advance this week do you think is most practice-changing?

#OncoAlert #Oncology #CancerResearch #PrecisionOncology #CancerUpdates